se of Serum Periostin Level to Predict Exacerbation in Moderate to Severe Asthma Patients

Not Applicable

Completed

• Conditions: moderate to severe asthma; Asthma; periostin

• Registration Number: TCTR20200525001
• Lead Sponsor: Department of medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-12-01
• Study Start: 2020-05-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

All patients were diagnosed moderate to severe asthma according to Global Strategy for Asthma Management and Prevention (GINA) updated 2018.
Ages over 18 years

Exclusion Criteria

Chronic obstructive pulmonary disease (COPD), asthma †COPD overlap, Idiopathic pulmonary fibrosis (IPF),pregnancy women and end-stage of chronic disease

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
serum periostin level and number of asthma exacerbation 24 weeks serum periostin level by ELISA

Secondary Outcome Measures

Name	Time	Method
symptom control 24 weeks Asthma Control Questionnaire (ACQ) and Asthma Control Test (ACT)